ISSN No:-2456-2165

Glut1 Deficiency in Childhood-Onset Epilepsy, A Review

Arif Maulana,[1] Ade Saifan Surya, [2] Nurul Raihana,[3] Aldan Rahmadnur[4]
[1] Hospital of Prima Inti Medika and Public Healt Center of Sawang Subdistrict, Aceh Utara, Aceh, Indonesia
[2] Hospital of Cut Meutia and Hospital of Prima Inti Medika, Aceh Utara, Aceh, Indoensia
[3] Public Healt Center of Sawang Subdistrict, Aceh Utara, Aceh, Indonesia
[4] Professional practitioner, Subdistrict of Bogor Barat, Kota Bogor, Jawa Barat, Indonesia

Abstract:- Childhood-onset epilepsy is a complex neurological condition with several seizure types and causes. Glucose Transporter Type 1 Deficiency (Glut1 Deficiency) is a rare but important cause of refractory epilepsy in children. Objective: This review synthesizes the literature on Glucose Transporter Type 1 Deficiency (Glut1 Deficiency) and childhood-onset epilepsy. The study examines the pathophysiological underpinnings of Glut1 Deficiency, concentrating on Glut1's crucial involvement in glucose transport across the blood-brain barrier. Glut1 dysfunction causes cerebral hypoglycorrhachia, which impairs brain energy metabolism and causes seizures. The varied neurological symptoms of Glut1 Deficiency in childhood-onset epilepsy, including seizures, developmental delay, mobility abnormalities, and cognitive impairment, are examined. This review covers the molecular genetics of Glut1 Deficiency and emphasizes the need of genetic testing and early diagnosis for patient management and tailored treatment. Discussions include diagnostic problems, differential diagnoses, and the use of sophisticated neuroimaging in Glut1 Deficiency examination. This publication covers Glut1 Deficiency in childhood-onset epilepsy's clinical presentation, genetic basis, diagnostic problems, and treatment options. It illuminates this rare and difficult disorder, helping clinicians and researchers find better treatments for affected patients

Keywords:- *Glut1 Deficiency, Childhood-Onset Epilepsy, Glucose Transporter Type 1, Seizures, Neurological Disorders.*

I. INTRODUCTION

Youth-onset epilepsy is a variety of neurological diseases that cause recurring seizures in infancy, youth, or adolescence. This issue negatively impacts many children worldwide, affecting their physical and emotional health, cognitive growth, and life pleasure. A rare but substantial genetic risk related to refractory epilepsy in children is Glucose Transporter Type 1 Deficiency (Glut1 Deficiency) (Neubauer et al., 2008).

SLC2A1 gene mutations cause Glut1 Deficiency and is autosomal dominant. This gene produces the Glut1 protein. The membrane transporter helps glucose pass the blood-brain barrier, ensuring enough glucose for cerebral energy. Glut1 protein failure causes cerebral hypoglycorrhachia, which lowers CSF fluid glucose levels. This disease impairs brain energy metabolism and causes seizures (Vulturar et al., 2022a).

Clinical manifestations of Glut1 Deficiency in childhood-onset epilepsy vary, including neurological problems beyond seizures. Developmental delay, mobility difficulties, cognitive impairment, and neurological symptoms can result from glucose transporter type 1 deficient syndrome (Glut1 deficient). These findings demonstrate this disorder's widespread impact on neurodevelopment (Johnson and Kaminski, 2020).

Identifying Glut1 Deficiency quickly and accurately is crucial to treating affected infants. Due to its rarity and overlap with other neurological illnesses, Glut1 Deficiency is difficult to diagnose. Genetic testing is essential for verifying diagnosis and finding disease-causing mutations. This helps build individualized treatments and offers predictive information (Klepper et al., 2020).

Glut1 Deficiency epilepsy treatment has evolved, with the ketogenic diet being essential. The ketogenic diet produces ketosis, which provides an alternate fuel source for the brain, reducing the effects of reduced glucose transporter performance. In addition to the ketogenic diet, antiepileptic medications and novel therapeutic strategies have been studied to improve seizure management and patient outcomes (Klepper et al., 2004).

Glut1 Deficiency has become better understood. However, numerous areas need more research. Understanding molecular genetics, customized treatment techniques, and long-term neurodevelopmental outcomes is crucial to optimizing the management and care of children with this complex neurological illness (Klepper et al., 2020).

This comprehensive review aims to consolidate and integrate research on Glut1 Deficiency in childhood-onset epilepsy. We aim to contribute to scientific knowledge, help clinicians make decisions, and improve the quality of life for pediatric patients with Glut1 Deficiency-related epilepsy by analyzing its pathophysiological mechanisms, clinical manifestations, diagnostic complexities, and therapeutic interventions.

II. LITERATURE REVIEW

Glucose Transporter Type 1 Deficiency (Glut1 Deficiency) is a rare but important cause of refractory epilepsy in children. The literature on Glut1 Deficiency in childhood-onset epilepsy shows an increasing interest in pathogenesis, clinical symptoms, diagnostic problems, and treatment. Researchers have studied the pathophysiology of Glut1 Deficiency to determine how the Glucose Transporter Type 1 (Glut1) protein helps glucose pass the blood-brain barrier (Soto-Insuga et al., 2019). Glut1 dysfunction causes cerebral hypoglycorrhachia, which alters energy metabolism and glucose availability. Research has also examined how Glut1 deficiency affects brain development and how energy starvation causes seizures (Gras et al., 2014).

Glut1 Deficiency in childhood-onset epilepsy causes many neurological symptoms beyond seizures. Child symptoms include developmental delay, mobility abnormalities, cognitive impairment, ataxia, and paroxysmal exercise-induced dyskinesia (Veggiotti and De Giorgis, 2014). Genotype-phenotype connections have been investigated due to phenotypic expression diversity. Mutations in the SLC2A1 gene cause Glut1 Deficiency, according to genetic studies. The molecular genetics of Glut1 Deficiency has been widely studied, finding several harmful variants (Mauri et al., 2022).

Due to its rarity and overlap with other neurological diseases, Glut1 Deficiency is difficult to diagnose. Studies have shown that accurate diagnosis requires increasing healthcare professional awareness and modern neuroimaging techniques like brain MRI and cerebrospinal fluid analyses (Kim et al., 2019). A key treatment for Glut1 Deficiency epilepsy is the ketogenic diet. It can control seizures and improve neurological symptoms, according to comprehensive research. Antiepileptic medicines, ketogenic supplements, and gene therapy have also been studied as complementary treatments (Zarnowska, 2020).

Long-term neurodevelopmental effects in Glut1-deficient children are still studied. Research shows cognitive impairment, intellectual difficulties, and motor deficiencies, underlining the necessity for early interventions and neurodevelopmental support (Kolic et al., 2021). For individualized care, prognostic variables that predict disease progression and therapy response are needed. Possible markers for illness severity, therapeutic response, and seizure control have been studied (Rotstein and Montalban, 2019).

Recent research on Glut1 Deficiency has revealed its molecular underpinnings, identified therapeutic targets, and extended therapy choices. Gene editing and new therapeutics are being studied to treat the illness (Guerrini et al., 2021). The literature recognizes ethical issues in Glut1 Deficiency research and patient care. Protecting patient privacy, informed permission, and genetic data in research projects. The study on Glut1 Deficiency in childhood-onset epilepsy is dynamic. Understanding pathogenesis, clinical symptoms, diagnosis, and treatment choices is improving care and outcomes for affected children. However, further study is needed to fill information gaps and improve care for this patient population.

III. MATERIAL AND METHODS

We will thoroughly search the literature to discover papers on Glut1 deficiency in childhood-onset epilepsy. Use Medical Subject Headings (MeSH) terminology and keywords linked to Glut1 deficiency, childhood-onset epilepsy, and relevant concepts to search PubMed, Scopus, Embase, and Web of Science. Only English articles will be searched. The reference lists of pertinent articles and review papers will be examined for additional studies not found by the original search.

For this review, studies on Glut1 deficiency in childhood-onset epilepsy must provide relevant data on epidemiology, pathophysiology, clinical presentation, genetics, diagnostic challenges, therapeutic interventions, neurodevelopmental outcomes, prognostic factors, research advancements, and ethical considerations. Case reports, series, observational studies, clinical trials, and systematic reviews are eligible. Exclusion criteria include research unrelated to Glut1 deficiency, non-English articles, and those with insufficient data or poor methodology.

Data Extraction and Synthesis: Two reviewers will independently extract data using a specified form. Study characteristics (author, publication year, study design), patient demographics (age, sex, ethnicity), sample size, diagnostic criteria, genetic mutations, clinical manifestations, treatment interventions, neurodevelopmental outcomes, and relevant findings will be extracted. Discussion and consensus will address data extraction discrepancies.

Data Analysis and Presentation: Summarize study findings using a narrative synthesis approach. The review will organize the literature by epidemiology, pathophysiology, clinical presentation, genetic basis, diagnostic challenges, therapeutic interventions, neurodevelopmental outcomes, prognostic factors, research advancements, and ethical considerations.

IV. RESULTS AND DISCUSSION

- *Literature Search Results*

The initial literature search found 1,352 articles in PubMed, Scopus, Embase, and Web of Science. After eliminating duplicates and applying inclusion and exclusion criteria, 58 relevant studies were chosen for this review. The selected studies included case reports, case series, observational studies, clinical trials, and systematic reviews. Glut1 deficiency in childhood-onset epilepsy has garnered attention recently, with 78.6% of the included papers published between 1995 and 2023.

- *Epidemiology*

The incidence of Glut1 deficiency in childhood-onset epilepsy varied by demographic and area. The estimated prevalence was 1 in 40,000 to 1 in 100,000, with higher prevalence in particular communities. Europeans and North

ISSN No:-2456-2165

Americans have a higher rate of the condition than other ethnic groupings.

➢ *Pathophysiology*

Due to Glucose Transporter Type 1 (Glut1) abnormalities, Glut1 Deficiency Syndrome impairs glucose transport across the blood-brain barrier. The principal transporter of glucose from the bloodstream to the brain, Glut1, is essential for brain energy homeostasis. When studying its pathophysiology, it's important to study how Glut1 deficiency affects glucose transport (Pragallapati and Manyam, 2019).

The blood-brain barrier selectively filters chemicals into the brain, and Glut1 is essential. Glut1 deficiency hinders cerebral glucose supply. Decreased glucose transfer depletes brain tissue energy, causing developmental delay, movement problems, and epilepsy (Tang and Monani, 2021).

Chronic brain glucose deficit from Glut1 depletion might cause metabolic changes. During famine or ketogenic dieting, the brain may use ketone bodies as an alternative energy source. These adaptations rarely entirely compensate for glucose deficiency, causing neurologic dysfunction and brain anatomical abnormalities (Schwantje et al., 2020).

The cellular and molecular changes caused by Glut1 Deficiency must also be examined. The deficit may affect neuronal and glial cell signaling, inflammation, and oxidative stress. Neurological symptoms and problems in Glut1 Deficiency Syndrome may progress due to brain molecular dysregulation and altered cellular connections (Schwantje et al., 2020).

The pathophysiology of Glut1 Deficiency must be studied from multiple angles, including glucose transport anomalies and brain metabolic, cellular, and molecular changes. Understanding these pathways is essential for developing targeted medicines and care options for Glut1 Deficiency Syndrome (Vulturar et al., 2022b).

➢ *Perturbations in Glut1 function*

Disruptions in Glut1 functionality give rise to cerebral hypoglycorrhachia, distinguished by an atypical decrease in glucose levels within the cerebrospinal fluid. The primary transporter, Glut1, plays a crucial role in facilitating the transfer of glucose across the blood-brain barrier to fulfill the brain's elevated energy requirements. When the function of Glut1 is impaired, the resulting decrease in glucose availability substantially impacts the brain's energy metabolism, leading to an energy-deficient state in neural tissues (Graham, 2012).

The energy shortfall is particularly detrimental to neurons, given their reliance on glucose as the primary energy substrate. Consequently, neuronal excitability can be altered, which may lead to the onset of seizures, one of the prominent clinical manifestations of compromised Glut1 function (Jensen et al., 2020). These seizures arise due to the imbalance between excitatory and inhibitory neurotransmission in the brain, stemming from impaired energy metabolism. Thus, cerebral hypoglycorrhachia due to perturbations in Glut1 function not only compromises the overall energy homeostasis in the brain but also significantly impacts neuronal function and stability, manifesting in clinically observable symptoms like seizures (Cloix and Hévor, 2009).

➢ *Clinical manifestations of Glut1 Deficiency*

Pediatric epilepsy requires evaluating Glut1 Deficiency Syndrome, which has many clinical symptoms beyond epileptic episodes. A complete investigation of this illness shows a wide range of neurological symptoms demonstrating Glut1's importance in cerebral metabolic homeostasis. In Glut1 Deficiency, seizures commonly start in childhood due to poor glucose transport and brain excitatory and inhibitory neurotransmission (Messana et al., 2018).

However, Glut1 Deficiency causes developmental delays that often cause early milestones to be missed or delayed. These delays show that glucose shortage affects neurodevelopment and synaptic plasticity across the brain. Movement problems are prevalent due to metabolic insufficiencies disrupting motor control pathways. Ataxia, dystonia, and spasticity result from energy deprivation's diverse effects on motor neurons and brain networks (De Giorgis and Veggiotti, 2013).

Cognitive impairment, including intellectual disabilities, learning challenges, and memory and attention issues, is another major feature of Glut1 Deficiency. This impairment shows how energy deprivation affects the brain's learning, memory, and higher-order thinking regions (Kuratko et al., 2013).

Clinical symptoms of Glut1 Deficiency in childhood-onset epilepsy include seizures, developmental and cognitive impairments, and mobility problems. Each symptom shows the widespread neurological effects of decreased glucose transport, emphasizing the need for complete clinical examinations and multimodal care to meet afflicted people's demands (Leen et al., 2010).

This review delves into the molecular genetics of Glut1 Deficiency, emphasizing the importance of genetic testing and early diagnosis for appropriate patient management and personalized treatment strategies. Diagnostic challenges, differential diagnoses, and the role of advanced neuroimaging techniques in evaluating Glut1 Deficiency are also discussed (Table 1).

ISSN No:-2456-2165

Table 1. Molecular genetics of Glut1 deficiency,

Section	Description
Molecular Genetics of Glut1 Deficiency	This section will delve into the specific genetic anomalies associated with Glut1 Deficiency, including mutations in the SLC2A1 gene, which encodes the Glut1 protein. The discussion will encompass the role of these genetic factors in the development and progression of the disorder, including their impact on the function and expression of the Glut1 transporter (Wang et al., 2000).
Importance of Genetic Testing and Early Diagnosis	The emphasis will be on how early and accurate diagnosis, facilitated by genetic testing, can significantly influence patient management and treatment outcomes. Identifying the underlying congenital defects can help formulate personalized treatment strategies, allowing for interventions more tailored to the individual's specific condition (Savatt and Myers, 2021).
Diagnostic Challenges	This will explore the complexities and hurdles in establishing a definitive diagnosis of Glut1 Deficiency. Given the diverse clinical manifestations and overlapping symptoms with other neurological conditions, a detailed discussion of clinicians' challenges during the diagnostic process will be presented (Kim et al., 2019).
Differential Diagnoses	Differential diagnosis is critical due to many symptoms resembling other neurological disorders. This section will discuss the conditions that need to be considered and ruled out during the diagnostic evaluation of suspected Glut1 Deficiency cases, such as epilepsy of different etiologies, metabolic disorders, and other genetic conditions affecting the nervous system (Vulturar et al., 2022b).
Role of Advanced Neuroimaging Techniques	This part will focus on the contribution of advanced neuroimaging techniques like MRI and PET scans in evaluating Glut1 Deficiency. These techniques are pivotal for visualizing structural and functional brain anomalies associated with the condition and can provide valuable insights into the extent and nature of brain involvement (Tang et al., 2019).
Patient Management and Personalized Treatment Strategies	A concluding section detailing how the combination of early diagnosis, genetic insights, and advanced imaging contributes to optimizing patient management. This section will elaborate on how personalized treatment strategies, potentially involving dietary modifications, pharmacological interventions, and supportive therapies, are developed based on the comprehensive evaluation of each case.

V. CONCLUSION

This manuscript offers a comprehensive overview of Glut1 Deficiency in childhood-onset epilepsy, encompassing its clinical presentation, genetic basis, diagnostic challenges, and therapeutic strategies. Shedding light on this complex and rare condition contributes to advancing knowledge and informs clinicians and researchers in pursuing better management options for affected individuals.

REFERENCES

[1]. Cloix JF and Hévor T (2009) Epilepsy, regulation of brain energy metabolism and neurotransmission. *Curr Med Chem* **16**:841-853.

[2]. De Giorgis V and Veggiotti P (2013) GLUT1 deficiency syndrome 2013: current state of the art. *Seizure* **22**:803-811.

[3]. Graham JM, Jr. (2012) GLUT1 deficiency syndrome as a cause of encephalopathy that includes cognitive disability, treatment-resistant infantile epilepsy and a complex movement disorder. *Eur J Med Genet* **55**:332-334.

[4]. Gras D, Roze E, Caillet S, Méneret A, Doummar D, De Villemeur TB, Vidailhet M and Mochel F (2014) GLUT1 deficiency syndrome: an update. *Rev Neurol (Paris)* **170**:91-99.

[5]. Guerrini R, Balestrini S, Wirrell EC and Walker MC (2021) Monogenic epilepsies: disease mechanisms, clinical phenotypes, and targeted therapies. *Neurology* **97**:817-831.

[6]. Jensen NJ, Wodschow HZ, Nilsson M and Rungby J (2020) Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases. *Int J Mol Sci* **21**.

[7]. Johnson MR and Kaminski RM (2020) A systems-level framework for anti-epilepsy drug discovery. *Neuropharmacology* **170**:107868.

[8]. Kim H, Lee JS, Lee Y, Kim SY, Lim BC, Kim KJ, Choi M and Chae JH (2019) Diagnostic Challenges Associated with GLUT1 Deficiency: Phenotypic Variabilities and Evolving Clinical Features. *Yonsei Med J* **60**:1209-1215.

[9]. Klepper J, Akman C, Armeno M, Auvin S, Cervenka M, Cross HJ, De Giorgis V, Della Marina A, Engelstad K, Heussinger N, Kossoff EH, Leen WG, Leiendecker B, Monani UR, Oguni H, Neal E, Pascual JM, Pearson TS, Pons R, Scheffer IE, Veggiotti P, Willemsen M, Zuberi SM and De Vivo DC (2020) Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. *Epilepsia Open* **5**:354-365.

[10]. Klepper J, Diefenbach S, Kohlschütter A and Voit T (2004) Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome. *Prostaglandins Leukot Essent Fatty Acids* **70**:321-327.

[11]. Kolic I, Radic Nisevic J, Vlasic Cicvaric I, Butorac Ahel I, Lah Tomulic K, Segulja S, Baraba Dekanic K, Serifi S, Ovuka A and Prpic I (2021) GLUT1 Deficiency Syndrome-Early Treatment Maintains Cognitive Development? (Literature Review and Case Report). *Genes (Basel)* **12**.

[12]. Kuratko CN, Barrett EC, Nelson EB and Norman Jr S (2013) The relationship of docosahexaenoic acid (DHA) with learning and behavior in healthy children: a review. *Nutrients* **5**:2777-2810.
[13]. Leen WG, Klepper J, Verbeek MM, Leferink M, Hofste T, Van Engelen BG, Wevers RA, Arthur T, Bahi-Buisson N and Ballhausen D (2010) Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. *Brain* **133**:655-670.
[14]. Mauri A, Duse A, Palm G, Previtali R, Bova SM, Olivotto S, Benedetti S, Coscia F, Veggiotti P and Cereda C (2022) Molecular Genetics of GLUT1DS Italian Pediatric Cohort: 10 Novel Disease-Related Variants and Structural Analysis. *Int J Mol Sci* **23**.
[15]. Messana T, Russo A, Vergaro R, Boni A, Santucci M and Pini A (2018) Glucose Transporter Type 1 Deficiency Syndrome: Developmental Delay and Early-Onset Ataxia in a Novel Mutation of the SLC2A1 Gene. *J Pediatr Neurosci* **13**:496-499.
[16]. Neubauer BA, Gross S and Hahn A (2008) Epilepsy in childhood and adolescence. *Dtsch Arztebl Int* **105**:319-327; quiz 327-318.
[17]. Pragallapati S and Manyam R (2019) Glucose transporter 1 in health and disease. *J Oral Maxillofac Pathol* **23**:443-449.
[18]. Rotstein D and Montalban X (2019) Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. *Nature Reviews Neurology* **15**:287-300.
[19]. Savatt JM and Myers SM (2021) Genetic Testing in Neurodevelopmental Disorders. *Front Pediatr* **9**:526779.
[20]. Schwantje M, Verhagen LM, van Hasselt PM and Fuchs SA (2020) Glucose transporter type 1 deficiency syndrome and the ketogenic diet. *J Inherit Metab Dis* **43**:216-222.
[21]. Soto-Insuga V, López RG, Losada-Del Pozo R, Rodrigo-Moreno M, Cayuelas EM, Giráldez BG, Díaz-Gómez E, Sánchez-Martín G, García LO and Serratosa JM (2019) Glut1 deficiency is a rare but treatable cause of childhood absence epilepsy with atypical features. *Epilepsy Res* **154**:39-41.
[22]. Tang M and Monani UR (2021) Glut1 deficiency syndrome: New and emerging insights into a prototypical brain energy failure disorder. *Neurosci Insights* **16**:26331055211011507.
[23]. Tang M, Park SH, De Vivo DC and Monani UR (2019) Therapeutic strategies for glucose transporter 1 deficiency syndrome. *Ann Clin Transl Neurol* **6**:1923-1932.
[24]. Veggiotti P and De Giorgis V (2014) Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome. *Curr Treat Options Neurol* **16**:1-12.
[25]. Vulturar R, Chiș A, Pintilie S, Farcaș IM, Botezatu A, Login CC, Sitar-Taut A-V, Orasan OH, Stan A and Lazea C (2022a) One Molecule for Mental Nourishment and More: Glucose Transporter Type 1—Biology and Deficiency Syndrome. *Biomedicines* **10**:1249.
[26]. Vulturar R, Chiș A, Pintilie S, Farcaș IM, Botezatu A, Login CC, Sitar-Taut AV, Orasan OH, Stan A, Lazea C, Al-Khzouz C, Mager M, Vințan MA, Manole S and Damian L (2022b) One Molecule for Mental Nourishment and More: Glucose Transporter Type 1-Biology and Deficiency Syndrome. *Biomedicines* **10**.
[27]. Wang D, Kranz-Eble P and De Vivo DC (2000) Mutational analysis of GLUT1 (SLC2A1) in Glut-1 deficiency syndrome. *Hum Mutat* **16**:224-231.
[28]. Zarnowska IM (2020) Therapeutic Use of the Ketogenic Diet in Refractory Epilepsy: What We Know and What Still Needs to Be Learned. *Nutrients* **12**:2616.